Patent ID: 8101180

Claim:
A method of following progress of a therapeutic regimen designed to alleviate a condition characterized by abnormal expression and/or activation of human insulin-like growth factor I receptor (IGF-IR) relative to normal comprising: a) assaying a sample from a subject to determine the level of expression and/or activation of said IGF-IR at a first time point; b) administering a humanized anti-IGF-IR antibody comprising: a light chain comprising complementary determining regions (CDRs) of SEQ ID NOs 2, 4, and 6, and human FR1, FR2, and FR3 amino acid sequences that correspond to those of a human germline, and a heavy chain comprising CDRs of SEQ ID NOs 8, 10, and 12, and human FR1, FR2, and FR3 amino acid sequences that correspond to those of a human germline, to said subject and assaying the level of expression and/or activation of said IGF-IR at subsequent time points following administration of said antibody; and c) comparing said level of said IGF-IR at said subsequent time points to the level determined in (a) as a determination of effect of said therapeutic regimen, wherein said anti-IGR-IR antibody: (i) binds IGF-IR but not IR alone, and/or (ii) inhibits the binding between a human IGF-IR and its native ligand with an IC 50 of less than 100 nM, and/or (iii) specifically inhibits the tyrosine kinase activity of said IGF-IR, and/or (iv) has a binding affinity of 10 nM or less for said IGF-IR, and/or (v) down-regulates IGF-IR expression, and/or (vi) inhibits in vivo tumor growth; and wherein a decrease in said level of expression and/or activation of IGF-IR subsequent to administration of said anti-IGF-IR antibody indicates a positive progression of the therapeutic regimen designed to alleviate said condition.